# Vitasora Health Limited (ASX: VHL)

**Investor Presentation** 


(Previously known as Respiri)



June 2025

# **Investment Highlights**

(RPM)



disease management

# Vitasora HEALTH

# Strategic Partnerships in Place



Recently established partnerships with significant U.S. healthcare entities enhancing Vitasora's reach in the US, including Evolent Health (NYSE: EVH) and The Physicians Alliance Corporation (TPAC)

## **Proven Management**



# **Business Overview**









Major clients in late-stage contract negotiations



**70,000** Current patient pipeline



**56%** Reduction in re-hospitalisations under Vitasora current programs

# Key Customers and Partnerships





Largest Healthcare system in Hawaii










Part of Tenet Health NYSE: THC - ~USD\$15b market cap



# Value-Based Care is the Recognised Goal; Execution the Barrier Remote Intervention Breaks it – Vitasora has Built it!





### Why are costs increasing?

### **Reactive Healthcare Delivery**

Limited preventative steps are taken once a patient leaves traditional healthcare settings. Traditional model of care is reactive and fails to develop personalised solutions for complex patients, leading to repeat hospitalisations and increased primary care costs

### **Ageing Population**

Demographic shifts are a significant drive of rising healthcare costs, as more baby boomers reach Medicare age

### Drivers of continued costs pressures

Growing portion of Americans >65 years of age Increasing number of Medicare insured Americans

Increasing prevalence of complex chronic conditions Current healthcare not designed for Chronic conditions

**RPM Addressable Market** 

These factors combined are expected to significantly increase the US RPM addressable market to USD\$30b by 2030 – a CAGR of 11.2%

# Vitasora RPM Platform Solution



Vitasora integrates connected medical devices to seamlessly capture real-time patient data, which is fed into its proprietary platform to enable continuous monitoring, personalised care coordination, and data-driven clinical decision-making.



### Vitasora Proprietary Patient Management Platform



**EMR** compatibility



**Remote clinical** services



Revenue optimisation tools



Productivity enhancement



Optimised clinical workflows



Intelligent data insights

# What does Vitasora do?

Vitasora has evolved from a respiratory focused connected care company into a full-service care management leader. Vitasora has created a connected care management platform that seamlessly integrates a wide range of medical devices - via Bluetooth or cellular connectivity - with its remote patient monitoring (RPM) software, enabling more comprehensive and personalised patient care. Vitasora is primarily focused on the U.S. healthcare market, supporting patients with chronic conditions.

This integrated approach enables healthcare providers to extend care beyond traditional clinical settings, aiming to improve patient outcomes and reduce hospital readmissions.



# Making it <u>E-A-S-Y</u> - Unlocking Value with Vitasora's **Unique Turnkey Service**



Patient is approved for monitoring

Device(s) provided to remotely monitor patient



hospitalisations



**Reduction** in length of hospital stay



- All Vitasora services are billable under distinct CPT codes





**Designated carer follow** up for minimum 20 minutes per month

Data storage and reporting to doctor for monitoring



Vitasora receives monthly payments via invoice to doctor



• Vitasora capabilities also include Chronic Care Management (CCM), Principal Care Management (PCM), Remote Therapeutic Monitoring (RTM), Transitional Care Management (TCM)

# Vitasora's key competitive advantages



One Stop Shop Fully integrated virtual care model



Full Suite Solution Wheezo device differentiator



Direct partnership with ACO's and payers under risk/capitated models & Clinic-in-Cloud ┓ ╮┓┓

### **Demonstrated Health**

outcomes; 50%+ reduction in hospital visits/readmissions, health outcomes & reduced Costs



## Turnkey implementation Making it E-A-S-Y: no workflow disruption, minimal practice involvement



FFS Generates US\$600 – US\$900/patient pa client revenue & US\$800-US\$1,300 VHL Revenue

# **Proven, Scalable Vitasora Patient Flow**

# **Patient Eligibility**

Identification and triage of at-risk patients into suitable care pathways, accompanied by the acquisition of essential demographic details.

# **Patient Approval**

Following consent, the patient's care plan and device provisioning are coordinated, with training appointments confirmed

# **Device Onboarding**

Device(s) are dispensed to the patient with comprehensive instruction on use and reporting intervals. Agreement on program expectations is established.

Vitasora personnel maintain regular patient contact and ensure compliance with care protocols, triaging escalations as appropriate.





# **Provider Visits**

At-risk individuals are evaluated and enrolled in relevant health programs, accompanied by the capture of essential demographic data.

# **Routine Telehealth** Monitoring

# Intervention

Clinicians are equipped with organized patient data, facilitating more informed and effective decisionmaking.

# **Uniquely Aligned Revenue Models**

Value Based Contracts – CMS mandated model



Population Health VHL charges mthly fee every member US\$5-\$40 + outcomes based annual bonus (\$XM) Dr Claims Reimbursement US\$100-\$200




FFS US\$60-\$90 Per patient per mth





# Fee For Service (FFS)



# Value Based Model Example

Example pilot program for 5000 patient value-based arrangement

Per Member Per Month Fee		
Patients in program	5,000	
Management fee (PMPM)	US\$20	
Yearly management fee per patient	US\$240	
Yearly revenue	US\$1.2m	

Risk share model	
Insurer total cost budget	US\$50m
Cost savings (% of budget)	10%
Vitasora portion of savings	US\$1.25m






Vitasora calculates that it will only need to actively manage 10-15% of the cohort, or 500-750 high risk patients

The remaining patients require minimal cost allocation and will simply be monitored by Vitasora


# **Vitasora Patient Programs and Patient Pipeline**






1. Vitasora forecasts, based on historical conversion rates, that it will convert approximately 30% of its patients into revenue-generating programs, which will be serviced via its RPM systems 2. 6,500 patient programs includes 4,063 existing patients, wit the remaining patients acquired through the acquisition of ORB in 2Q24

3. IPEC = Universal Patient Engagement Centre Services



# **Rapidly Expanding Patient Pipeline Through Unique Contractual Arrangements**






# **Additional New Clients In Late-Stage Contract Discussions**

ortunity	Number of CMS Medicare / Medicaid Patients
DME	500,000
ed Value Based Model	20,000
nsurer	200,000
care Organisation (Hospital + ACO)	350,000
based HCO	150,000
	1,220,000

Expected access to an additional ~1.2m CMS Medicare / Medicaid patients from new clients

# Management outlook for Vitasora

Growth from expanding lives covered with existing customers and adding new large scale health care organisations.





# **Board and Management**



## Nicholas Smedley Chairman

Mr Smedley is an experienced Investment Banker and M&A Advisor, with 14 years' experience at UBS and KPMG. He has worked on M&A transactions in the UK, Hong Kong, China, and Australia with transactions ranging from the A\$9bn defence of WMC Resources through to the investment of \$65m into Catch.com.au. Nicholas currently oversees investments in the Property, Aged care, Technology and Medical Technology space. Key areas of expertise include M&A, Debt structuring, Corporate governance and innovation. He holds a Bachelor of Commerce from Monash University.



# Marjan Mikel Chief Executive Officer

Marjan has been at the helm of Respiri taking it from R&D to commercialisation since 2019. A highly experienced managing director and board member with a career spanning Australia, Europe, Japan and the US, Marjan's focus has been in the healthcare industry; from pharmaceuticals and information services and technology to medical devices and sleep disorder solutions. He founded and subsequently sold Healthy Sleep Solutions after developing it into a successful business, with ResMed Ltd as a joint venture/shareholder partner.

Currently, Marjan also acts as commercial advisor to BlueBell Health, a mental health company, and is an industry research fellow at University of New South Wales Faculty of Engineering.





## Jonathan Adams Non-executive Director

Jonathan Adams currently serves as an Investment Director at Mt. Vernon Investments, LP. Mr. Adams joined Vernon Investments in 2007 and is primarily responsible for sourcing, structuring, and executing private equity venture capital investments across direct, co-investments, and select fund investments. Prior to joining Mt. Vernon Investments, Mr. Adams was an accountant at PricewaterhouseCoopers. Mt. Adams holds both a BBA and an MPA from The University of Texas at Austin. Mr. Adams is a CFA® charterholder and a Certified Public Accountant in the State of Texas.

Mr. Adams served as Chairman of the Board for Orb Health, Inc. and also serves as a Board Director for TTI Acquisition, LLC, parent company of TTI Sports International. Mr. Adams serves as a Board Observer for multiple portfolio company investments of Mt. Vernon Investments. Mr. Adams resides in Dallas, TX with his wife and family.

# **USA Senior Management**



## Marjan Mikel Chief Executive Officer

Over 35 years of strategic leadership across a diverse spectrum of healthcare organizations, with deep expertise in remote patient monitoring (RPM), medical devices, business SaaS, and pharmaceuticals. Demonstrated success in driving and executing large-scale commercial transactions within the healthcare and SaaS sectors.



### **Peter Hildebrandt** Chief Operations Officer

Over two decades of global business leadership driving innovation in B2B technology companies across a broad range of industrial applications. Former CEO of Advanced Braking Technology and eHatsystems, with a strong track record of strategic growth and operational excellence.



### Eric Van Portfliet Chief Technology Officer

Over 40 years of experience as a software engineer and technology executive, with a distinguished track record of leading innovation across healthcare technology organisations. Served as Chief Technology Officer at four companies, most recently at Orb Health - successfully acquired by Vitasora.

### Serena Gutierrez Vice President Patient Experience & Innovation

Over 20 years of expertise in population health, leading the design and implementation of clinical integration strategies and quality improvement initiatives within healthcare organisations. Specialised in value-based care with a strong focus on delivering measurable outcomes that benefit both patients and providers.





### Mat Robie Chief Commercial Officer

Over 20 years of specialised experience in the U.S. healthcare sector, serving as a trusted consultant and executive director across a broad spectrum of healthcare organisations. Deep expertise in Medicare, Medicaid, and commercial operations, with a proven ability to navigate complex regulatory and operational landscapes.





# Thank you

# Get in touch

Marjan Mikel Chief Executive Officer / Managing Director T +61 0408 462 873

E marjan@vitasorahealth.com


Vitasora

16

Appendix



# **Target Customers – Healthcare Providers**





# **Target Customers**

Primary care provider (PCP's)

**US** health insurers

**Hospital systems** 

Accountable care organisation (ACO's)

Independent practice association (IPA's)

### Key outcomes for customers



**Reduction** in length of hospital stay



Reduction in emergency room visits



Improvement in medication compliance

# **Key Government Body Support for a Solution**

### "CMS moves closer to Accountable care goals"

### Summary of announcement

CMS has mandated and made substantial progress toward its goal of having all individuals with traditional Medicare (fee-for-service) in a care relationship that holds providers accountable for quality and total cost by 2030

### **Outcome for Vitasora**

Endorsement of Vitasora's strategy in the expanding U.S. healthcare market, where remote patient services programs are emerging as key, cost effective components of the essential healthcare investment mix



Proposed CPT changes is forecasted to have 100% increase in monitoring services delivered by Vitasora's clinical staff - **US\$70-90 to US\$140-180 pppm** 

1. <u>https://www.cms.gov/newsroom/fact-sheets/cms-moves-accountable-care-goals-2025-aco-initiatives</u>

2. https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02877032-3A654884


## "AMA recommends significant expansion of remote care"

### Summary of announcement

AMA announced proposed changes to reimbursement criteria for RPM programs, making it easier for providers to claim reimbursement for certain services

### **Outcome for Vitasora**

# Patient RPM Billing Journey



Vitasora RPM Billing

